Pasithea regains Nasdaq minimum bid price compliance, delisting risk removed

Pasithea Therapeutics Corp.

Received Nasdaq letter on Jan 17, 2024 confirming compliance with $1.00 minimum bid price rule.
Stock held closing bid at or above $1.00 for sufficient consecutive business days to satisfy requirement.
Previously received non-compliance notice on Jan 19, 2023 and extension to Jan 15, 2024.
Matter is now closed; no further action needed regarding bid price deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.